These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1113 related articles for article (PubMed ID: 8875231)

  • 1. Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumor protection conferred by IL-2 secreting cancer vaccines.
    Schweighoffer T; Schmidt W; Buschle M; Birnstiel ML
    Gene Ther; 1996 Sep; 3(9):819-24. PubMed ID: 8875231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.
    Hu HM; Urba WJ; Fox BA
    J Immunol; 1998 Sep; 161(6):3033-41. PubMed ID: 9743368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovirus-enhanced receptor-mediated transferrinfection for the generation of tumor vaccines.
    Schweighoffer T; Berger M; Buschle M; Schmidt W; Birnstiel ML
    Cytokines Mol Ther; 1996 Sep; 2(3):185-91. PubMed ID: 9384703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen-experienced CD4(+) T cells limit naïve T-cell priming in response to therapeutic vaccination in vivo.
    Schiering C; Guarnerio J; Basso V; Muzio L; Mondino A
    Cancer Res; 2010 Aug; 70(15):6161-70. PubMed ID: 20631073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.
    Aruga A; Aruga E; Chang AE
    Cancer Res; 1997 Aug; 57(15):3230-7. PubMed ID: 9242454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination.
    Maass G; Schmidt W; Berger M; Schilcher F; Koszik F; Schneeberger A; Stingl G; Birnstiel ML; Schweighoffer T
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5540-4. PubMed ID: 7777545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
    Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
    Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution.
    Ma J; Urba WJ; Si L; Wang Y; Fox BA; Hu HM
    Eur J Immunol; 2003 Aug; 33(8):2123-32. PubMed ID: 12884286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens.
    Mattner F; Fleitmann JK; Lingnau K; Schmidt W; Egyed A; Fritz J; Zauner W; Wittmann B; Gorny I; Berger M; Kirlappos H; Otava A; Birnstiel ML; Buschle M
    Cancer Res; 2002 Mar; 62(5):1477-80. PubMed ID: 11888923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional CD25- and CD25+ mucosal regulatory T cells are induced in gut-draining lymphoid tissue within 48 h after oral antigen application.
    Hauet-Broere F; Unger WW; Garssen J; Hoijer MA; Kraal G; Samsom JN
    Eur J Immunol; 2003 Oct; 33(10):2801-10. PubMed ID: 14515264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells incubated with irradiated tumor cells effectively stimulate T lymphocyte activation and induce enhanced expression of CD69, CD25 as well as production of IFNgamma and IL4.
    Stegel V; Kopitar A; Jezersek Novaković B; Ihan A; Novaković S
    Int Immunopharmacol; 2006 Jan; 6(1):79-89. PubMed ID: 16332516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
    Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
    J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.